Interim report RIAS A/S

Udgivet den 17-08-2016  |  kl. 11:00  |  

Interim report RIAS A/S

The development in the company's third quarter of the accounting year 2015/16 has overall progressed as expected. However, as in the first half year by a much differentiated trend in this quarter, where the industrial sector's revenue has stagnated and the building & constructions sector's has regained some of the lost revenue.

Sales in the company's building products has surprised positively and is slightly better compared to the first half of the financial year 2015/16. A slightly higher activity can be observed in the building merchants and DIY shops within the company's products. However, the earning margin remains under pressure as a result of the fierce competition.

The general activity level in the industrial sector is still in line with the expectations from the half-year report 2015/16. It is once again domestic demand and especially advertising-based materials that has shown positive growth rates.

By contrast, the sales targeting export-oriented Danish companies has stagnated, and sales of industrial products has been on par with last year, while sales within the processing area has fallen back. Sales to export markets is developing positively and as expected.

Specially a strong competition in the processing area has meant a drop in revenue in the third quarter. This is primarily caused by the loss of two major customers. Thus the processing area failed to meet the expected growth.

Capacity costs are at a lower level than last year despite continuing investments in the strategic development of the export and processing department.

Based on this background the Board of RIAS still expects a result level for the accounting year 2015/16 of DKK 7-9 million before tax against a result of DKK 5,6 million in the previous year.

Yours faithfully

RIAS A/S

 

Henning Hess

Vedhæftede filer:

2016 08 Interim report RIAS AS.pdf

Udgivet af: NPinvestordk

Seneste nyheder

17:49 Europa/lukning: Danske fedmeaktier blødte og trak Europa i rødt
17:19 Fredagens obligationer: Renter faldt efter amerikanske inflationstal
17:18 Novo banket i bund efter skuffende data - aktionærerne tabte omkring 690 mia. kr.
17:06 Fredagens aktier: Øretæver til Novo Nordisk og Zealand Pharma giver solid C25-nedtur
15:46 USA/åbning: Eli Lilly vinder på Novos kollaps mens inflationsdata skærer lidt af dykket
15:17 Jeudan har milliarder klar til opkøb: "Øget optimisme kan give flere transaktioner i 2025"
15:15 Novo/Jyske Bank: Kursreaktion virker som overreaktion
14:29 USA/tendens: Eli Lilly vinder på Novos kollaps mens frygt for nedlukning varsler rød start
13:33 Korr: Udsalg af Novo-aktier presser kronen
13:24 Udsalg af Novo-aktier presser kronen
12:29 Sydbank-analytiker: Voldsomt kursfald afspejler skuffelsen over Cagrisema-data
12:25 Europa/aktier: Danske fedmeaktier bløder og trækker Europa i rødt
12:22 Novo smadres på børsen efter skuffende fedmestudie - aktien taber 770 mia. kr.
12:11 Novos styrtdyk trækker C25-indekset ned i sit fjerdestørste fald nogensinde
12:09 Gubra og Zealand Pharma trækkes med ned af negativt nyt til Novo Nordisk
12:05 Novo lever ikke op til egne forventninger i vigtigt studie - aktien mister 900 mia kr -NY2
11:56 Novo lever ikke op til egne forventninger i kursfølsomt studie - aktien mister 700 mia kr
11:48 Aktier/middag: Zealand Pharma bankes tocifret ned efter FDA-afvisning og trækker C25 ned
11:28 Obligationer/middag: Små renteudsving før inflationsnyt fra USA
10:49 Jefferies ser kurslussing til Zealand Pharma som købsmulighed